Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 323

The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.

MET-dependent solid tumours — molecular diagnosis and targeted therapy

Open access
Guo, Robin, Luo, Jia, Chang, Jason, Rekhtman, Natasha, Arcila, Maria, Drilon, Alexander·2020·Nature Reviews Clinical Oncology

Abstract

Attempts to develop MET-targeted therapies have historically focused on MET-expressing cancers, with limited success. Thus, MET expression in the absence of a genomic marker of MET dependence is a poor predictor of benefit from MET-targeted therapy. However, owing to the development of more sensitive methods of detecting genomic alterations, high-level MET amplification and activating MET mutations or fusions are all now known to be drivers of oncogenesis. MET mutations include those affecting the kinase or extracellular domains and those that result in exon 14 skipping. The activity of MET tyrosine kinase inhibitors varies by MET alteration category. The likelihood of benefit from MET-targeted therapies increases with increasing levels of MET amplification, although no consensus exists on the optimal diagnostic cut-off point for MET copy number gains identified using fluorescence in situ hybridization and, in particular, next-generation sequencing. Several agents targeting exon 14 skipping alterations are currently in clinical development, with promising data available from early-phase trials. By contrast, the therapeutic implications of MET fusions remain underexplored. Here we summarize and evaluate the utility of various diagnostic techniques and the roles of different classes of MET-targeted therapies in cancers with MET amplification, mutation and fusion, and MET overexpression. Therapies targeting MET-overexpressing cancers have limited efficacy. However, owing to advances in detection methods, therapies targeting MET -dependent tumours harbouring MET amplifications, activating mutations or fusions are emerging. In this review, the authors describe emerging data on this new class of targeted therapies. The degree of MET amplification is a continuous variable that can be measured using fluorescence in situ hybridization or next-generation sequencing. No consensus exists on the most appropriate diagnostic cut-off point for MET amplification. Patients with solid tumours harbouring high-level MET amplifications have a greater likelihood of benefit from single-agent or combination MET-targeted therapies than those with lower MET copy number gains. MET mutations are highly heterogeneous and can range from those that involve the MET kinase domain to those that result in MET exon 14 skipping. The activity of type I or type II MET tyrosine kinase inhibitors can substantially differ by MET mutation type. A wide variety of MET fusions have been identified, although the biology of these alterations and their implications for responses to MET-targeted therapies are not well characterized. MET overexpression in the absence of a known driver of MET dependence is a poor predictor of benefit from MET-targeted therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41571-020-0377-z

Cites

210 of 210 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 210 references

Cited by

See all 323

Metadata

Authors
Guo, R., Luo, J., Chang, J., Rekhtman, N., Arcila, M., & Drilon, A.
Venue
Nature Reviews Clinical Oncology
Published
2020-06-08
Volume
17
Issue
9
Pages
569-587
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W3033982788
Cited by
323
References
210
FWCI
8.37
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MET-dependent solid tumours — molecular diagnosis and targeted therapy. https://app.cochat.ai/papers/10.1038/s41571-020-0377-z
The paper
Guo, R., Luo, J., Chang, J., Rekhtman, N., Arcila, M., & Drilon, A. (2020). MET-dependent solid tumours — molecular diagnosis and targeted therapy. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-020-0377-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.